Page 1

SPAGO NANOMEDICAL AB Interim report January- September , 2021 TumoradⓇ moves closer to clinical trials JULY - SEPTEMBER IN BRIEF ● ● Net sales for the quarter amounted to KSEK 195 ( KSEK 67 ) . The loss for the quarter amounted to KSEK -10,103 ( KSEK -4,485 ) . Operating expenses for the quarter amounted to KSEK -11,756 ( KSEK -6,011 ) . Earnings per share , before and after dilution , for the quarter amounted to SEK -0.26 ( SEK -0.14 ) . Cash and cash equivalents at the end of the quarter amounted to KSEK 65,987 ( KSEK 35,699 ) . JANUARY - SEPTEMBER IN BRIEF Net sales for the year amounted to KSEK 561 ( KSEK 167 ) . The loss for the year amounted to KSEK -27,778 ( KSEK -14,304 ) . Operating expenses for the year amounted to KSEK -32,645 ( KSEK -19,050 ) . Earnings per share , before and after dilution , for the year amounted to SEK -0.67 ( SEK -0.56 ) . SIGNIFICANT EVENTS DURING THE QUARTER Paul Hargreaves was appointed Chief Development Officer ( CDO ) . Paul will join the management team and have a key role in the clinical development of the company's project portfolio . SIGNIFICANT EVENTS AFTER THE QUARTER Agreement was signed with the global CRO Cmed Group Limited for the development of the first clinical study with the company's therapy project Tumoad . Spago Nanomedical AB ( org . no . 556574-5048 ) – Interim report January - September , 2021 spago NANOMEDICAL